Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells
Figure 2
Effects of γ-tocotrienol, PPARγ agonist rosiglitazone and troglitazone treatment alone or in combination on growth of (a) MCF-7 and (b) MDA-MB-231 human breast cancer cells. MCF-7 cells were initially plated at a density of (6 wells per group) in 24-well plates and (b) MDA-MB-231 were initially plated at a density of (6 wells per group) in 96-well culture plates and exposed to treatment media for a 4-day period. Afterwards, viable cell number was determined using MTT colorimetric assay. Vertical bars indicate the mean cell count ± SEM in each treatment group. as compared with vehicle-treated controls and as compared to their corresponding control treated with γ-tocotrienol alone.
